Aarti Drugs' Q3 FY 2025-26 Quarterly Results

Result Summary

• Aarti Drugs Ltd reported a 7.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 6.1%.
• Its expenses for the quarter were down by 3.1% QoQ and up 10.8% YoY.
• The net profit decreased 10.2% QoQ and increased 9.3% YoY.
• The earnings per share (EPS) of Aarti Drugs Ltd stood at 4.44 during Q3 FY 2025-26.

Financial Statments for Q3 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aarti Drugs Ltd is a prominent player within the pharmaceutical industry, primarily engaged in the manufacturing of bulk drugs and chemicals. Its main products include active pharmaceutical ingredients (APIs), intermediates, specialty chemicals, and formulations. The company is known for its significant contributions to the production of antibiotics, anti-protozoal, and anti-inflammatory medications. As of the current data, there are no recent major developments or strategic shifts publicly available for Aarti Drugs Ltd. The company operates in a highly competitive and regulated industry, where compliance with stringent quality standards is paramount.

Revenue

In the quarter ending Q3FY26, Aarti Drugs Ltd reported a total income of ₹602.94 crores. This reflects a quarter-over-quarter (QoQ) decrease of 7.6% compared to the previous quarter, Q2FY26, where the total income was ₹652.88 crores. However, on a year-over-year (YoY) basis, there was a 6.1% increase from Q3FY25, when the total income stood at ₹568.50 crores. This fluctuation in revenue is indicative of the dynamic nature of the pharmaceutical market, influenced by various factors including product demand and market competition.

Profitability

For the quarter Q3FY26, Aarti Drugs Ltd reported a profit before tax of ₹29.03 crores and a profit after tax of ₹40.55 crores. Compared to Q2FY26, there was a significant decline of 51.9% in profit before tax, which was previously ₹60.41 crores. The profit after tax also saw a decrease of 10.2% from ₹45.16 crores in the previous quarter. On a year-over-year basis, the profit before tax decreased by 42.8% from Q3FY25, which was ₹50.76 crores, while profit after tax increased by 9.3% from ₹37.09 crores in the same period last year. The earnings per share for Q3FY26 was ₹4.44, down by 10.3% from the previous quarter but up by 9.4% compared to Q3FY25.

Operating Metrics

In the analysis of the company's operating metrics for Q3FY26, total expenses were recorded at ₹573.91 crores, representing a 3.1% decrease from Q2FY26's expenses of ₹592.47 crores. However, when compared to the same quarter in the previous year, Q3FY25, expenses rose by 10.8% from ₹517.74 crores. The tax component for Q3FY26 showed a notable adjustment, with a reversal or net tax benefit of ₹11.52 crores, contrasting with a tax expense of ₹15.25 crores in Q2FY26 and ₹13.67 crores in Q3FY25. This reversal has a considerable impact on the profit after tax figures for the quarter.